Tagged with NUS

India Pharma News: Generics-Only Guidelines on Hold; Torrent/Cipla Deal; Lupin BI Brands Acquisition

India India Pharma News: Generics-Only Guidelines on Hold; Torrent/Cipla Deal; Lupin BI Brands Acquisition

India A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory; the government’s revision of Good Manufacturing Practices (GMP) in light of deaths linked to Indian-made cough syrups; Torrent Pharma’s new…

India Pharma News: Sanofi Demerger; Junshi/Dr. Reddy’s Partnership; Venus Remedies Approvals

India India Pharma News: Sanofi Demerger; Junshi/Dr. Reddy’s Partnership; Venus Remedies Approvals

India Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and Ferring’s maternal health agreement and Ipca Laboratories and Sun Pharma’s quality issues. Zydus Lifesciences reports smallest profit in 14…

India Pharma News: Sun’s Concert Acquisition; BMS Expanded Footprint; Cipla FDA Scrutiny

India India Pharma News: Sun’s Concert Acquisition; BMS Expanded Footprint; Cipla FDA Scrutiny

India The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and the Cipla manufacturing site under FDA scrutiny. Dr. Reddy’s to buy Mayne Pharma’s US business for USD 105 million…

Building a Globally Competitive Innovation Ecosystem in Singapore

Singapore Building a Globally Competitive Innovation Ecosystem in Singapore

Singapore Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from government, academia, and industry weigh in on what Singapore’s current performance and future potential as an innovation hub, translating its…

Ashok Venkitaraman – Director, Cancer Science Institute of Singapore; Distinguished Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS); Director, NUS Center for Cancer Research; Program Director, Disease Intervention Technology Laboratory, Agency for Science, Technology & Research (A*STAR)

Singapore Ashok Venkitaraman – Director, Cancer Science Institute of Singapore; Distinguished Professor of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS); Director, NUS Center for Cancer Research; Program Director, Disease Intervention Technology Laboratory, Agency for Science, Technology & Research (A*STAR)

Singapore Professor Ashok Venkitaraman introduces his work in Singapore, coordinating and catalysing research on the causes of cancer in Asia, and translating this research to clinical impact through improved detection, treatment and prevention. Professor Venkitaraman also outlines how the Singaporean research ecosystem compares to that of his former base in Cambridge,…

Hong Kong Biotech IPOs since Listing Reform in April 2018

Hong Kong Hong Kong Biotech IPOs since Listing Reform in April 2018

Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page